{"id":31207,"date":"2016-10-19T11:47:21","date_gmt":"2016-10-19T18:47:21","guid":{"rendered":"http:\/\/lifeboat.com\/blog\/2016\/10\/crispr-based-startups-rush-to-ipo-and-dont-seem-to-care-that-we-dont-know-who-officially-owns-crispr"},"modified":"2017-06-04T09:21:12","modified_gmt":"2017-06-04T16:21:12","slug":"crispr-based-startups-rush-to-ipo-and-dont-seem-to-care-that-we-dont-know-who-officially-owns-crispr","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2016\/10\/crispr-based-startups-rush-to-ipo-and-dont-seem-to-care-that-we-dont-know-who-officially-owns-crispr","title":{"rendered":"CRISPR-based startups rush to IPO and don\u2019t seem to care that we don\u2019t know who officially owns CRISPR"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/crispr-based-startups-rush-to-ipo-and-dont-seem-to-care-that-we-dont-know-who-officially-owns-crispr.jpg\"><\/a><\/p>\n<p>CRISPR Therapeutics\u2014a Swiss startup hoping to harness the gene-editing technology it\u2019s named after to develop treatments for genetic illnesses like sickle-cell anemia and cystic fibrosis\u2014 <a href=\"http:\/\/pitchbook.com\/newsletter\/crispr-sets-ipo-terms\">went public today<\/a> (Oct. 19), raising $56 million in its initial public offering. It\u2019s the third CRISPR-related biotech to IPO this year despite a pitched battle over who owns the patent to the breakthrough technique.<\/p>\n<p>The market for CRISPR (short for \u201cclustered regularly interspaced short palindromic sequences\u201d) is projected to be worth more than $5.5 billion by 2021, nearly double its current value, <a href=\"http:\/\/www.prnewswire.com\/news-releases\/genome-editinggenome-engineering-market-worth-554-billion-usd-by-2021-596521031.html#continue-jump\">according to research firm MarketsandMarkets<\/a>. The potential of the cheap, easy-to-use technology\u2014which could do everything from <a href=\"http:\/\/qz.com\/662784\/a-loophole-is-letting-genetically-modified-foods-sidestep-american-gmo-regulations\/\">creating a mushroom that doesn\u2019t brown<\/a> to <a href=\"http:\/\/qz.com\/713040\/us-bioethicists-just-approved-a-human-gene-editing-trial-and-sean-parker-is-footing-the-bill\/\">curing cancer<\/a> by cutting and pasting snippets of DNA\u2014has companies rushing to develop new applications even though no one knows who will ultimately control it.<\/p>\n<p>\u201cIt\u2019s a race,\u201d says Fabien Palazzoli, head of biotech intellectual property (IP) analytics for the consulting firm IPStudies. \u201cIt\u2019s a race for the IPO, for the scientific results, for the FDA recommendation, for the IP.\u201d<\/p>\n<p><!-- Link: <a href=\"http:\/\/qz.com\/813552\/crispr-therapeutics-ipo-raised-56-million-but-the-companys-future-is-in-jeopardy-because-of-the-crispr-patent-war\/\">http:\/\/qz.com\/813552\/crispr-therapeutics-ipo-raised-56-milli...atent-war\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CRISPR Therapeutics\u2014a Swiss startup hoping to harness the gene-editing technology it\u2019s named after to develop treatments for genetic illnesses like sickle-cell anemia and cystic fibrosis\u2014 went public today (Oct. 19), raising $56 million in its initial public offering. It\u2019s the third CRISPR-related biotech to IPO this year despite a pitched battle over who owns the [\u2026]<\/p>\n","protected":false},"author":413,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-31207","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/31207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/413"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=31207"}],"version-history":[{"count":2,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/31207\/revisions"}],"predecessor-version":[{"id":59995,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/31207\/revisions\/59995"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=31207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=31207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=31207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}